Gemoxen200 mg/vial

Gemoxen is a cytotoxic chemotherapy agent administered only under the supervision of an oncology specialist as part of a physician-directed cancer treatment protocol. Its use is classified by strength of evidence as follows:

Established / FDA-approved indications

• Pancreatic cancer: First-line treatment of locally advanced (non-resectable stage II or stage III) or metastatic adenocarcinoma of the pancreas, including patients previously treated with fluorouracil.
• Non-small cell lung cancer (NSCLC): First-line treatment of inoperable, locally advanced (stage IIIA or IIIB) or metastatic (stage IV) NSCLC, in combination with cisplatin.
• Breast cancer: In combination with paclitaxel, for metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.
• Ovarian cancer: In combination with carboplatin, for advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.

Guideline-supported / commonly used off-label indications

• Bladder (urothelial) cancer: In combination with cisplatin, as a guideline-recognised regimen for locally advanced or metastatic urothelial carcinoma, particularly when cisplatin-based standard regimens are not suitable.
• Biliary tract cancer (cholangiocarcinoma/gallbladder cancer): In combination with cisplatin, a guideline-supported regimen for advanced biliary tract cancers.
• Other malignancies such as soft-tissue sarcoma and malignant mesothelioma, used off-label in select cases based on oncologist judgment and institutional protocols.

The exact indication, combination partner, and treatment protocol for Gemoxen are always determined by the treating oncologist based on cancer type, stage, and patient fitness.

Each vial contains Gemcitabine (as gemcitabine hydrochloride) as the active ingredient, supplied as a sterile, white to off-white lyophilized powder for reconstitution and intravenous infusion. It is commonly available in single-dose vial strengths of 200 mg, 1 g, and 2 g of Gemcitabine base.

Gemoxen is a cytotoxic, cell-cycle-specific antineoplastic (anticancer) medicine belonging to the nucleoside analog (pyrimidine antimetabolite) class. It is chemically related to cytarabine but has a distinct spectrum of anticancer activity and metabolism.

Gemoxen is given exclusively as an intravenous infusion in a hospital or specialized oncology infusion setting, as part of combination or single-agent chemotherapy regimens for various solid tumors. It is not available as an oral or self-administered product, and dosing/scheduling is individualized by the treating oncologist according to disease type, treatment protocol, and the patient's blood counts and organ function.

Antineoplastic agent – Antimetabolite (deoxycytidine/pyrimidine nucleoside analog); Gemoxen is used as cytotoxic chemotherapy.

Gemcitabine is a pyrimidine (deoxycytidine) nucleoside analog that is cell-cycle-phase specific, killing cells undergoing DNA synthesis (S-phase) and also blocking progression of cells through the G1/S-phase boundary.

After cellular uptake, Gemcitabine is phosphorylated intracellularly by nucleoside kinases to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) metabolites.

• dFdCDP inhibits ribonucleotide reductase, which is responsible for catalysing the reactions that generate deoxynucleoside triphosphates needed for DNA synthesis; this reduces the pool of deoxynucleotides, including dCTP.
• dFdCTP competes with dCTP for incorporation into DNA. Once incorporated, only one additional nucleotide is added to the growing DNA strand, after which further DNA synthesis is inhibited ("masked chain termination"), leading to programmed cell death (apoptosis).

The reduction in dCTP pools by dFdCDP also enhances the incorporation of dFdCTP into DNA (self-potentiation), contributing to the drug's cytotoxic activity.

Gemoxen is administered exclusively as an intravenous (IV) infusion, typically over about 30 minutes, by trained oncology nursing/medical staff in a hospital or specialized chemotherapy infusion unit. It is not for self-administration, oral use, or home use. Care is taken to avoid extravasation (leakage of the drug into surrounding tissue) at the infusion site, as this can cause local tissue injury.

Clinically significant interactions with Gemoxen include:

• Radiation therapy: Gemoxen is a potent radiosensitizer. Concurrent (same-week) administration with radiotherapy can markedly increase the severity of mucosal and other tissue toxicity within the radiation field; concurrent use requires specific, radiation-modified protocols. Gemoxen can also cause "radiation recall" reactions (inflammation at a site of previous radiation) even when given well after radiotherapy has ended.
• Other myelosuppressive chemotherapy or radiotherapy: Combining Gemoxen with other bone-marrow-suppressing drugs or radiation increases the risk of severe neutropenia, thrombocytopenia, and anemia; blood counts require close monitoring (see Precautions and Warnings).
• Live vaccines: Because Gemoxen is immunosuppressive, live or live-attenuated vaccines should generally be avoided during treatment due to risk of disseminated vaccine-strain infection.
• Cisplatin and other platinum agents: Used intentionally in combination protocols, but this combination increases overall hematologic and renal toxicity, requiring closer monitoring.

Patients should inform their oncologist of all other medicines, supplements, and any planned vaccinations before and during Gemoxen therapy.

Side effects of Gemoxen are common because it is a cytotoxic chemotherapy agent. Serious toxicities are covered fully under Precautions and Warnings; this section lists the overall frequency pattern.

Very common

• Myelosuppression (low white blood cell, platelet, and red blood cell counts) — see Precautions and Warnings
• Nausea and vomiting
• Elevated liver enzymes (transaminases, alkaline phosphatase)
• Flu-like symptoms (fever, chills, headache, myalgia, fatigue), usually within hours of infusion
• Rash and mild itching
• Hair thinning/hair loss (usually mild)
• Mild proteinuria and hematuria
• Peripheral edema

Less common but clinically important

• Diarrhea, stomatitis (mouth sores)
• Injection/infusion site reactions
• Constipation

Rare but serious (see Precautions and Warnings for full detail)

• Severe pulmonary toxicity (interstitial pneumonitis, pulmonary edema, capillary leak syndrome, ARDS)
• Hemolytic uremic syndrome (HUS) / thrombotic microangiopathy
• Severe hepatotoxicity including liver failure
• Posterior reversible encephalopathy syndrome (PRES)
• Severe skin reactions

Pregnancy: Gemoxen can cause fetal harm based on its mechanism of action (it is genotoxic/cytotoxic to dividing cells) and findings in animal reproduction studies. Gemoxen should not be used during pregnancy. Women of reproductive potential should undergo pregnancy testing before starting treatment and use effective contraception during treatment and for a defined period after the last dose (as advised by the oncologist); this recommendation also applies to male patients with female partners of reproductive potential. If pregnancy occurs during treatment, the patient should be advised of the potential risk to the fetus and referred promptly for specialist counselling.

Lactation: It is not known whether Gemoxen passes into human breast milk. Because of the potential for serious adverse effects in a breastfed infant, breastfeeding should be discontinued during treatment with Gemoxen and is not recommended for a period after the last dose, as advised by the treating physician.

Gemoxen is a cytotoxic drug with a narrow safety margin and must be administered only under close specialist supervision, with regular laboratory monitoring. Key warnings include:

Myelosuppression

Gemoxen commonly causes dose-related suppression of bone marrow function, resulting in neutropenia, thrombocytopenia, and/or anemia, which may be severe. Complete blood counts must be obtained before each dose, and doses may need to be reduced, delayed, or withheld based on the degree of marrow suppression. Neutropenic patients are at increased risk of serious infection.

Pulmonary toxicity

Gemoxen has been associated with pulmonary toxicity ranging from mild dyspnea to severe events such as pulmonary edema, interstitial pneumonitis, capillary leak syndrome, and acute respiratory distress syndrome (ARDS), which can be fatal. Treatment should be interrupted immediately if unexplained or worsening dyspnea or evidence of severe pulmonary toxicity develops, and supportive care instituted.

Hemolytic uremic syndrome (HUS) / thrombotic microangiopathy

Gemoxen can cause hemolytic uremic syndrome and thrombotic microangiopathy, a rare but life-threatening toxicity that can result in irreversible renal failure and death. Renal function, hemoglobin, and platelet counts should be monitored during treatment; Gemoxen must be discontinued permanently at the first sign of microangiopathic hemolytic anemia (e.g. rapidly falling hemoglobin with schistocytes, thrombocytopenia, rising bilirubin/LDH, and worsening renal function), and appropriate management (which may include plasmapheresis) initiated promptly.

Hepatotoxicity

Gemoxen can cause elevations in liver enzymes and, rarely, serious hepatotoxicity including liver failure and death, particularly in patients with pre-existing liver metastases, hepatitis, alcoholism, or cirrhosis. Liver function should be assessed before and periodically during treatment.

Posterior reversible encephalopathy syndrome (PRES)

Rare cases of PRES — presenting with headache, seizures, altered mental status, and visual disturbances, with characteristic findings on brain imaging — have been reported with Gemoxen. If PRES is suspected, Gemoxen should be discontinued and blood pressure and neurological symptoms managed; the condition is usually reversible with prompt treatment.

Capillary leak syndrome

Gemoxen can cause capillary leak syndrome, with generalized edema, weight gain, hypotension, and, in severe cases, pulmonary edema and cardiovascular compromise; this requires prompt discontinuation and supportive management.

Extravasation

Care must be taken to avoid extravasation during infusion, as leakage of Gemoxen into surrounding tissue can cause local tissue injury.

Radiation therapy

See Interactions for details on radiosensitization and radiation recall risk with Gemoxen.

Because Gemoxen is a cytotoxic agent, it should be handled and administered according to institutional guidelines for hazardous drugs, by trained oncology personnel only.

There is no known specific antidote for Gemoxen overdose. Overdosage would be expected to intensify the known adverse effects of Gemoxen, particularly severe myelosuppression (with risk of serious infection and bleeding), gastrointestinal toxicity, and other organ toxicities described under Precautions and Warnings.

Because Gemoxen is administered only in a hospital/oncology setting under direct medical supervision, suspected overdose should be managed immediately by the treating medical team with close monitoring of blood counts and organ function, supportive care, and, if needed, transfer to an appropriate level of care or contact with emergency/poison control services. There is no specific reversal agent; management is supportive.

Store unopened Gemoxen powder for injection vials at room temperature (20°C to 25°C / 68°F to 77°F; excursions permitted to 15°C–30°C), protected from light, in the original carton. After reconstitution, the solution should be used promptly; if not used immediately, reconstituted Gemoxen solution is generally stable for a limited period at room temperature only and must NOT be refrigerated, as refrigeration may cause crystallization. Keep out of reach of children, and dispose of unused solution according to institutional cytotoxic waste procedures.

Renal impairment: Gemoxen should be used with caution in patients with renal impairment, as they may be at increased risk of toxicity; renal function should be monitored closely, and dose modification considered by the treating oncologist. Gemoxen is contraindicated/must be discontinued if hemolytic uremic syndrome develops (see Precautions and Warnings).

Hepatic impairment: Gemoxen should be used with caution in patients with pre-existing liver disease, including hepatic metastases, hepatitis, or cirrhosis, due to increased risk of hepatotoxicity; liver function should be monitored before and during treatment.

Elderly patients: Clinical studies of Gemoxen have included patients over 65 years of age, and overall differences in safety or effectiveness compared with younger patients have not been consistently observed; however, greater sensitivity in some older individuals cannot be ruled out, so dosing is individualized with close monitoring.

Pediatric patients: see Pediatric Uses.

Pregnancy and breastfeeding: see Pregnancy and Lactation.

The duration of Gemoxen treatment is determined by the treating oncologist and is individualized based on the cancer type, treatment protocol, response to therapy, and tolerability. Treatment is generally continued for a defined number of cycles or until disease progression, unacceptable toxicity, or a decision by the oncologist and patient to stop, whichever occurs first. Patients should not alter or stop Gemoxen treatment on their own without consulting their oncology team.

Gemoxen for injection is supplied as a sterile lyophilized powder that must be reconstituted before use by a qualified healthcare professional, using appropriate aseptic technique:

• Reconstitute using preservative-free 0.9% Sodium Chloride Injection (normal saline) only, in the volume specified by the vial strength/manufacturer's instructions, to achieve a solution concentration not exceeding 40 mg/mL (higher concentrations may cause incomplete dissolution and increase the risk of adverse reactions).
• Shake gently to dissolve completely; the reconstituted solution should be a clear, colorless to light straw-colored solution, free of visible particulate matter.
• The required dose is then further diluted, if needed, in 0.9% Sodium Chloride Injection for intravenous infusion.
• Reconstituted Gemoxen solution should not be refrigerated, as crystallization may occur; use within the time period specified by institutional protocol/manufacturer guidance, and discard any unused portion as cytotoxic waste.

Antineoplastic agents; Antimetabolites; Nucleoside analogs (deoxycytidine/pyrimidine analog); Gemcitabine belongs to this cytotoxic chemotherapy drug class.

Gemcitabine is a prodrug that is converted intracellularly to its active diphosphate and triphosphate metabolites. The diphosphate metabolite inhibits ribonucleotide reductase, depleting deoxynucleotide pools needed for DNA synthesis, while the triphosphate metabolite is incorporated into DNA in place of cytidine, causing masked chain termination after one further nucleotide is added. This blocks DNA synthesis and repair, leading to cell-cycle arrest (mainly at the G1/S boundary) and apoptosis of rapidly dividing cancer cells. Gemcitabine is most active against cells in the S-phase of the cell cycle.

D

The safety and effectiveness of Gemoxen in pediatric patients have not been established for routine clinical use, and Gemoxen is not FDA-approved for children. Some pediatric oncology clinical trials have evaluated Gemoxen in specific malignancies, but data are limited and use in children should occur only within a formal clinical trial or specialized pediatric oncology protocol under the direct supervision of a pediatric oncologist, with close monitoring for the toxicities described under Precautions and Warnings.